Get Adobe Flash player

БЛИСК І ЗЛИДНІ АНТИРЕТРОВІРУСНОЇ ТЕРАПІЇ ВІЛ-ІНФЕКЦІЇ

Автор: Дьяченко А. Г., Дьяченко П. А.,Городченко К. М

Сторінки: 372-384

Анотація

            

Досягнення антиретровірусної терапії (АРТ) значно поліпшили якість життя ВІЛ-інфікованих людей. Втім, попри потужну комбіновану терапію чутливі методи часто виявляють низький рівень віремії. До того ж у багатьох пацієнтів спостерігаються транзиторні випадки віремії вище рівня детекції. Нездатність АРТ виділити вірус навіть у тих пацієнтів, у яких він не визначається протягом багатьох років, пов’язана з наявністю персистентної інфекції в деяких клітинних та анатомічних резервуарах. Очевидно, латентні резервуари є головною перешкодою ерадикації ВІЛ. Крім того, навіть глибока супресія вірусної реплікації не відновлює в повному обсязі імунний статус, порушений унаслідок ВІЛ-інфекції. Це відбувається внаслідок хронічної активації імунної системи, викликаної підвищенням проникності кишкового бар’єра та транслокацією бактерій та продуктів їх розпаду. Прогрес в ерадикації інфекції потребує нових підходів у боротьбі з латентністю та імунодефіцитом.

 

Ключові слова: вірус імунодефіциту людини (ВІЛ), ВІЛ-інфекція, латентність, антиретровірусна терапія (АРТ), мікробна транслокація (МТ), імунна активація. 

 

*Ця електронна адреса захищена від спам-ботів. вам потрібно увімкнути JavaScript, щоб побачити її.

Список літератури

1. Maraviroc for previously treated patients with R5 HIV-1 infection / R. M. Gulick, J. Lalezari, J. Goodrich [et al.] // N. Engl. J. Med. – 2008. – Vol. 359. – P. 1429–41.

2. Raltegravir with optimized background therapy for resistant HIV-1 infection / R. T. Steigbigel, D. A. Cooper, P. N. Kumar [et al.] // N. Engl. J. Med. – 2008. – Vol. 359. – P. 339–354.

3. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies/ J. A. Sterne, M. May, D. Costagliola [et al.] // Lancet. – 2009. – Vol. 373. –P. 1352–1363.

4. Effect of early versus deferred antiretroviral therapy for HIV on survival / M. M. Kitahata, S. J. Gange, A. G. Abraham [et al.] // N. Engl. J. Med. – 2009. – Vol. 360. – P. 1815–1826.
5. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study / S. Emery, J. A. Neuhaus, A. N. Phillips [et al.] // J. Infect. Dis. – 2008. – Vol. 197. – P. 1133–1144.
6. UNAIDS. Report on the global AIDS epidemic: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). – 2008. – P. 1–36.
7. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy / V. D. Lima, R. S. Hogg, P. R. Harrigan [et al.] // Aids. – 2007. – Vol. 21. – P. 685–692.
8. Collaboration TATC. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies // The Lancet. – 2008. – Vol. 372. – P. 293–299.
9. Changes in the risk of death after HIV seroconversion compared with mortality in the general population / K. Bhaskaran, O. Hamouda, M. Sannes [et al.] // JАМА. – 2008. – Vol. 300. – P. 51.
10. Deeks S. G. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity / S. G. Deeks, A. N. Phillips // BМJ. – 2009. – Vol. 338. – P. 3172.
11. Changes in causes of death among adults infected by HIV between 2000 and 2005: The “Mortalite 2000 and 2005” surveys (ANRS EN19 and Mortavic) / C. Lewden, T. May, E. Rosenthal [et al.] // J. Acquir. Immune Defic. Syndr. – 2008. – Vol. 48. – P. 590–598.
12. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease / V. A. Triant, H. Lee, C. Hadigan, S. K. Grinspoon // J. Clin. Endocrinol. Metab. – 2007. – Vol. 92. – P. 2506–2512.
13. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4 + T cells / M. A. French, M. S. King, J. M. Tschampa [et al.] // J. Infect. Dis. – 2009. – Vol. 200. – P. 1212–1215.
14. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection / L. H. Kuller, R. Tracy, W. Belloso [et al.] // PLoS Med. – 2008. – Vol. 5:e203.
15. United Nations General Assembly. Political declaration on HIV/AIDS: intensifying our efforts to eliminate HIV/AIDS. United Nations General Assembly Resolution 65/277. – New York, United Nations, 2011.
16. WHO, UNICEF, UNAIDS. Progress report 2011. Global HIV/AIDS response Epidemic update and health sector progress towards universal access. WHO, UNICEF, UNAIDS. Geneva, Switzerland. – December, 2011.
17. US Food and Drugs Administration. Antiretroviral drugs used in the treatment of HIV infection, 2012.
18. Viral blip dynamics during highly active antiretroviral therapy / M. Di Mascio, M. Markowitz, M. Louie [et al.] // J. Virol. – 2003. – Vol. 77. – Р. 12165–12172.
19. Preferred antiretroviral drugs for the next decade of scale up / I. Andrieux-Meyer, A. Calmy, P. Cahn [et al.] // J. Int. AIDS Soc. – 2012. – Vol. 15. – Р. 17986.
20. Bartlett J. G. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents / J. G. Bartlett, H. C. Lane. – 2007. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
21. Shen L. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection / L. Shen, R. F. Siliciano // J. Allergy Clin. Immunol. – 2008. – Vol. 122 (1). – P. 22–28.
22. Douek D. HIV Disease Progression: Immune Activation, Microbes, and a Leaky Gut / D. Douek // Top. HIV Med. – 2007. – Vol. 15 (4). – P. 114–117.
23. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time / A. S. Perelson, A. U. Neumann, M. Markowitz [et al.] // Science. – 1996. – Vol. 271. – P. 1582–1586.
24. Decay characteristics of HIV-1-infected compartments during combination therapy / A. S. Perelson, P. Essunger, Y. Cao [et al.] // Nature. – 1997. – Vol. 387. – P. 188–91.
25. Finzi D. Viral dynamics in HIV-1 infection / D. Finzi, R. Siliciano // Cell. – 1998. – Vol. 93. – Р. 665–671.
26. Rong L. Modeling Latently Infected Cell Activation: Viral and Latent Reservoir Persistence, and Viral Blips in HIV-infected Patients on Potent Therapy / L. Rong, A. S. Perelson // PLoS Comput Biol. – 2009. – Vol. 5 (10): e1000533. doi:10.1371/journal.pcbi.1000533.
27. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy / S. Palmer, F. Maldarelli, A. Wiegand [et al.] // Proc. Natl. Acad. Sci. USA. – 2008. – Vol. 105. – Р. 3879–3884.
28. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy / G. Dornadula, H. Zhang, B. VanUitert [et al.] // JAMA. – 1999. – Vol. 282. – Р. 1627–1632.
29. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy / B. Ramratnam, J. E. Mittler, L. Zhang [et al.] // Nat. Med. – 2000. – Vol. 6. – Р. 82–85.
30. Duration of an intermittent episode of viremia / M. Di Mascio, J. K. Percus, O. E. Percus [et al.] // Bull. Math. Biol. – 2005. – Vol. 67. – Р. 885–900.
31. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission / D. M. Smith, J. K. Wong, H. Shao [et al.] // J. Infect. Dis. – 2007. – Vol. 196. – Р. 356–360.
32. Induction of HIV-1 replication in latently infected CD4 + T cells using a combination of cytokines / T. W. Chun, D. Engel, S. B. Mizell [et al.] // J. Exp. Med. – 1998. – Vol. 188. – Р. 83–91.
33. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection / T. W. Chun, L. Carruth, D. Finzi [et al.] // Nature. – 1997. – Vol. 387. – Р. 183–188.
34. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4 + T cells / J. D. Siliciano, J. Kajdas, D. Finzi [et al.] // Nat. Med. – 2003. – Vol. 9. – Р. 727–728.
35. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads / D. Persaud, G. K. Siberry, A. Ahonkhai [et al.] // J. Virol. – 2004. – Vol. 78. – Р. 968–979.
36. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4 + T cells / J. R. Bailey, A. R. Sedaghat, T. Kieffer [et al.] // J. Virol. – 2006. – Vol. 80. – Р. 6441–6457.
37. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART / R. E. Nettles, T. L. Kieffer, P. Kwon [et al.] // JAMA. – 2005. – Vol. 293. – Р. 817–1829.
38. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy / S. Palmer, F. Maldarelli, A. Wiegand [et al.] // Proc. Natl. Acad. Sci. USA. – 2008. – Vol. 105. – Р. 3879–3884.
39. Douek D. HIV Disease Progression: Immune Activation, Microbes, and a Leaky Gut / D. Douek // Top. HIV Med. – 2007. – Vol. 15(4). – P. 114–117.
40. Weight loss, the gut and the inflammatory response in aids patients / T. P. Stein, B. Koerner, M. D. Schluter [et al.] // Cytokine. – 1997. –Vol. 9. – P. 143–147.
41. Pathogenesis of HIV infection: What the virus spares is as important as what it destroys / Z. Grossman, M. Meier-Schellersheim, W. E. Paul , L. J. Picker // Nat. Med. – 2006. – Vol. 12. – P. 289–295.
42. Severe CD4 + T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy / M. Guadalupe, E. Reay, S. Sankaran [et al.] // J. Virol. – 2003. – Vol. 77. – P. 11708–11717.
43. Massive infection and loss of memory CD4 + T cells in multiple tissues during acute SIV infection / J. J. Mattapallil, D. C. Douek, B. Hill [et al.] // Nature. – 2005. – Vol. 434. – P. 1093–1097.
44. Biology of CCR5 and its role in HIV infection and treatment / M. M. Lederman, A. Penn-Nicholson, M. Cho, D. Mosier // JAMA. – 2006. – Vol. 296. – P. 815–826.
45. CD+4 T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract / J. M. Brenchley, T. W. Schacker, L. E. Ruff [et al.] // J. Exp. Med. – 2004. – Vol. 200. – P. 749–759.
46. Microbial translocation is a cause of systemic immune activation in chronic HIV infection / J. M. Brenchley, D. A. Price, T. W. Schacker [et al.] // Nat. Med. – 2006. – Vol. 12. – P. 1365–1371.
47. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage / J. V. Giorgi, L. E. Hultin, J. A. McKeating [et al.] // J. Infect. Dis. – 1999. – Vol. 179. – P. 859–870.
48. Antiretroviral therapy corrects HIV-1-induced expansion of CD8 + CD45RA+ CD27− CD11a(bright) activated T cells / L. Yin, C. A. Rodriguez, W. Hou [et al.] // J. Allergy Clin. Immunol. – 2008. – Vol. 122. – P. 166–172.
49. Damaged Intestinal Epithelial Integrity Linked to Microbial Translocation in Pathogenic SIV Infections / J. D. Estes, L. D. Harris, N. R Klatt. [et al.] // PLoS Pathog. – 2010. – Vol. 6 (8): e1001052. doi:10.1371/journal.ppat.1001052.
50. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients / P. Ancuta, A. Kamat, K. J. Kunstman [et al.] // PLoS ONE. – 2008. – 3: e2516.
51. Cell-cycle dysregulation in the immunopathogenesis of AIDS / M. Paiardini, B. Cervasi, R. Dunham [et al.] // Immunol. Res. – 2004. – Vol. 29. – P. 253–268.
52. Perturbations of cell cycle control in T cells contribute to the different outcomes of simian immunodeficiency virus infection in rhesus macaques and sooty mangabeys / M. Paiardini, B. Cervasi, B. Sumpter [et al.] // J. Virol. – 2006. – Vol. 80. – P. 634–642.
53. Inadequate clearance of translocated bacterial products in HIV-infected humanized mice / U. Hofer, E. Schlaepfer, S. Baenziger [et al.] // PLoS Pathog. 2010;6 doi: 10.1371/journal.ppat.1000867.
54. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: The role of interleukin 7 and interleukin 7 receptor alpha and microbial translocation / R. Rajasuriar, D. Booth, A. Solomon [et al.] // J. Infect. Dis. – 2010. – Vol. 202. – P. 1254–1264. doi: 10.1086/656369.
55. Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy / S. Piconi, D. Trabattoni, A. Gori [et al.] // AIDS. – 2010. – Vol. 24. – P. 1991–2000.doi: 10.1097 /QAD. 0b013e32833c93ce.
56. Simian immunodeficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection / Q. Li, J. D. Estes, L. Duan [et al.] // J. Infect. Dis. – 2008. – Vol. 197. – P. 420–429.
57. Brenchley J. M. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections / J. M. Brenchley, M. Paiardini, K. S. Knox // Blood. – 2008. – Vol. 112. – P. 2826–2835.
58. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection / D. Favre, S. Lederer, B. Kanwar [et al.] // PLoS Pathog 2009;5:e1000295.
59. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis / A. Gori, C. Tincati, G. Rizzardini [et al.] // J. Clin. Microbiol. – 2008. – Vol. 46. – P. 757–758.
60. Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviral-Treated HIV Infection / W. Jiang, M. M. Lederman, P. Hunt [et al.] // J. Infect. Dis. – 2009. – Vol. 199. – P. 1177–1185.